| Lab | Valuation | Founded | Space | HQ | Founders | More | Jobs |
|---|---|---|---|---|---|---|---|
| Xaira Therapeutics | ~$4B | 2024 | Bio / AI drug discovery | San Francisco | Marc Tessier-Lavigne, David Baker, Hetu Kamisetty | Details | Apply |
| insitro | ~$2.5B | 2018 | Bio / AI drug discovery | South San Francisco | Daphne Koller | Details | Apply |
| Generate Biomedicines | ~$2B | 2018 | Bio / AI drug discovery | Somerville, MA | Geoffrey von Maltzahn, Molly Gibson, Gevorg Grigoryan, Avak Kahvejian, Noubar Afeyan | Details | Apply |
| Recursion | ~$1.75B (mkt cap) | 2013 | Bio / AI drug discovery | Salt Lake City | Chris Gibson, Dean Li, Blake Borgeson | Details | Apply |
| Chai Discovery | $1.3B | 2024 | Bio / AI drug discovery | San Francisco | Joshua Meier, Jack Dent | Details | Apply |
| EvolutionaryScale | >$1B | 2024 | Bio / AI drug discovery | New York | Alexander Rives, Tom Sercu, Salvatore Candido | Details | Apply |
| Earendil Labs | ~$1B | 2023 | Bio / AI drug discovery | Wilmington, DE | Bo Chen | Details | — |
| Genesis Therapeutics | ~$1B | 2019 | Bio / AI drug discovery | Burlingame, CA | Evan Feinberg, Ben Sklaroff | Details | Apply |
| Owkin | $1B | 2016 | Bio / AI drug discovery | Paris / New York | Thomas Clozel, Gilles Wainrib | Details | Apply |
| Schrödinger | ~$1B (mkt cap) | 1990 | Bio / AI drug discovery | New York | Richard Friesner, William Goddard | Details | Apply |
✓ confirmed valuation * rumored or estimated ~ approximate > lower bound < upper bound (mkt cap) public market cap (acq.) acquisition price
Founders: Geoffrey von Maltzahn, Molly Gibson, Gevorg Grigoryan, Avak Kahvejian, Noubar Afeyan